Core Viewpoint - European stocks rose as better-than-expected U.S. personal consumption expenditure data boosted investor sentiment, overshadowing President Trump's proposed tariffs on patented drugs [1] Group 1: Market Performance - The Stoxx Europe 600 index closed up 0.8% [1] - The healthcare sector erased earlier losses, closing up 0.1% despite Trump's announcement of a 100% tariff on patented drugs starting October 1, unless manufacturers establish production in the U.S. [1] Group 2: Company Reactions - Novo Nordisk's stock fell by 3.5%, and Zealand Pharma's stock dropped by 2.4% following the tariff announcement [1] - Bank J. Safra Sarasin's equity strategist, Wolf von Rotberg, indicated that the lack of policy details and the limited number of affected drugs would not lead to a reduction in pharmaceutical sector holdings [1] Group 3: Investment Strategy - Sophie Huynh, a portfolio manager and strategist at Société Générale, suggested that the current situation might be a good time to increase holdings in European stocks rather than shorting them [1] - The pharmaceutical sector's performance is highly dependent on specific countries, and while the current situation may create market tension, investors should maintain a broader perspective [1]

Group 1 - European stock markets have seen an increase, with the German DAX index rising over 1% [1] - The French CAC 40 index has increased by nearly 1% [1] - The Euro Stoxx 50 index has gained 0.77% [1] - The UK FTSE 100 index has risen by 0.3% [1]

Group 1 - European stock markets experienced significant gains, with the Euro Stoxx 50 index rising by 2.6% [1] - The German DAX index increased by 2.5% [1] - The UK FTSE 100 index surged by over 3% [1] - The French CAC 40 index saw a rise of 2.7% [1]